Two cases of aseptic meningitis with simultaneous presence of antibodies to lymphocytic choriomeningitis (LCM) and mumps viruses were observed. In the 1st patient antibodies to both viruses appeared in sera and cerebrospinal fluid (CSF). The 2nd patient displayed rising serum antibodies to both viruses and CSF antibodies to mumps virus. Immunological findings and clinical features of the patients are discussed.
Objective. The study presents results of the low-intensity intravenous (IV) laser radiation effect on some indicators of the hemostasis system and respiratory function of 83 patients with a chronic lung disease (COPD), stable phase, II-III (after GOLD scale), including 51 men and 32 women. The average COPD duration was 9.6±4.4 years.
Materials and methods. All patients with COPD were randomly divided into 2 groups - comparison (30 people) and main (53 people). The control group consisted of 20 practically healthy people, matched by sex and age. Patients in the control group received only standard drug therapy with IGCC/DBA combination (budesonide/formoterol, salmeterol/fluticasone propionate inhalation at a therapeutic dose corresponding to the COPD clinical symptoms severity).
Result and Discussion. In addition to the basic treatment, the main group received a course of intravenous lowintensity laser radiation. As established before the treatment initiation, patients with COPD experienced a decrease in FEV1, Tiffno index, SaO2.
Conclusion. The respiratory function disruption was accompanied by a significant activation of plasma hemostasis ( prothrombin time shortening, thrombin time, activated partial thromboplastin time) and a significant increase in platelet aggregation (increase in the aggregation degree, aggregation rate, decrease in the aggregation time). At the same time, in patients with COPD, a significant decrease in anticoagulant activity was observed before treatment, particularly antithrombin III decrease when compared with the control group (p <0.05) and CRP (main group: 0.86±0.02; control group: 0.85±0.02). The introduction of low-intensity laser radiation into the patients complex with COPD led to the these parameters normalization.
Bangladesh Journal of Medical Science Vol.18(3) 2019 p.586-592
Autoimmune polyendocrine syndrome type 1 (APS type 1) is a disease characterized by a variety of clinical manifestations resulting from the involvement of multiple endocrine and non-endocrine organs in the pathological process. APS type 1 is a rare genetically determined disease with autosomal recessive inheritance. Mutations in the autoimmune regulator gene (AIRE) lead to a disruption of the mechanism of normal antigen expression and the formation of abnormal clones of immune cells, and can cause autoimmune damage to organs. Within APS type 1, the most common disorders are primary adrenal insufficiency, hypoparathyroidism, and chronic candidiasis. Some understudied clinical manifestations of APS type 1 are autoimmune pathological processes in the eye: keratoconjunctivitis, dry eye syndrome, iridocyclitis, retinopathy, retinal detachment, and optic atrophy. This review presents the accumulated experimental and clinical data on the development of eye damage of autoimmune nature in APS type 1, as well as the laboratory and instrumental methods used for diagnosing the disease. Changes in the visual organs in combination with clinical manifestations of hypoparathyroidism, adrenal insufficiency and candidiasis should lead the clinical doctor to suspect the presence of APS type 1 and to examine the patient comprehensively. Timely genetic counselling will allow early identifi cation of the disease, timely prescription of appropriate treatment and prevention of severe complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.